Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.09

Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.09), versus ($0.19) reported last year. Revenue for the quarter came in at $139 million, versus $512 million reported last year.

Based on current plans, the Company estimates that it has capital resources to reach beyond the final analysis of SEAMLESS and continue existing programs through the end of 2017.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c